• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

众之力：个性化癌症治疗中代表性趋化因子和代谢物G蛋白偶联受体的多层次靶向作用

The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.

作者信息

Inverso Donato, Tacconi Carlotta, Ranucci Serena, De Giovanni Marco

机构信息

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Vita-Salute San Raffaele University, Milan, Italy.

出版信息

Eur J Immunol. 2024 Dec;54(12):e2350870. doi: 10.1002/eji.202350870. Epub 2024 Sep 12.

DOI:10.1002/eji.202350870
PMID:39263783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628915/
Abstract

G protein-coupled receptors (GPCRs) are vital cell surface receptors that govern a myriad of physiological functions. Despite their crucial role in regulating antitumor immunity and tumorigenesis, therapeutic applications targeting GPCRs in oncology are currently limited. This review offers a focused examination of selected protumorigenic chemokine and metabolite-sensing GPCRs. Specifically, the review highlights five GPCRs able to orchestrate tumor immunobiology at three main levels: tumor immunity, cancer cell expansion, and blood vessel development. The review culminates by illuminating emerging therapies and discussing innovative strategies to harness the full potential of GPCR-targeted treatments, by applying a multireceptor and patient-specific logic.

摘要

G蛋白偶联受体（GPCRs）是至关重要的细胞表面受体，调控着无数的生理功能。尽管它们在调节抗肿瘤免疫和肿瘤发生中起着关键作用，但目前针对GPCRs的肿瘤学治疗应用仍然有限。本综述聚焦于选定的促肿瘤趋化因子和代谢物感知GPCRs进行研究。具体而言，该综述重点介绍了五种能够在肿瘤免疫生物学的三个主要层面发挥作用的GPCRs：肿瘤免疫、癌细胞增殖和血管生成。通过应用多受体和患者特异性策略，本文阐述了新兴疗法，并探讨了充分发挥GPCR靶向治疗潜力的创新策略，以此作为总结。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/a2d09741bb09/EJI-54-2350870-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/24cf7384883f/EJI-54-2350870-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/36e9cae095ac/EJI-54-2350870-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/a2d09741bb09/EJI-54-2350870-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/24cf7384883f/EJI-54-2350870-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/36e9cae095ac/EJI-54-2350870-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7c/11628915/a2d09741bb09/EJI-54-2350870-g004.jpg

相似文献

1
The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.众之力：个性化癌症治疗中代表性趋化因子和代谢物G蛋白偶联受体的多层次靶向作用
Eur J Immunol. 2024 Dec;54(12):e2350870. doi: 10.1002/eji.202350870. Epub 2024 Sep 12.
2
Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.肿瘤学中 G 蛋白偶联受体的药物治疗靶向：已批准疗法和新兴概念的实例。
Drugs. 2017 Jun;77(9):951-965. doi: 10.1007/s40265-017-0738-9.
3
Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.揭示肿瘤 G 蛋白偶联受体组：新型 G 蛋白偶联受体驱动的肿瘤内分泌网络和癌症免疫治疗靶点。
J Biol Chem. 2019 Jul 19;294(29):11062-11086. doi: 10.1074/jbc.REV119.005601. Epub 2019 Jun 5.
4
Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?代谢物感应 G 蛋白偶联受体：癌症治疗的有前途的治疗靶点？
Cells. 2020 Oct 23;9(11):2345. doi: 10.3390/cells9112345.
5
G protein-coupled receptors as promising cancer targets.G蛋白偶联受体作为有前景的癌症靶点。
Cancer Lett. 2016 Jul 1;376(2):226-39. doi: 10.1016/j.canlet.2016.03.031. Epub 2016 Mar 18.
6
G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression.G 蛋白偶联受体介导的免疫调节信号在肿瘤进展中的作用。
FASEB J. 2024 Jul 31;38(14):e23829. doi: 10.1096/fj.202400458R.
7
Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies.免疫肿瘤治疗中靶向G蛋白偶联受体
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):315-331. doi: 10.1146/annurev-pharmtox-061724-080852. Epub 2024 Dec 17.
8
G protein-coupled receptor-targeted proteolysis-targeting chimeras in cancer therapeutics.癌症治疗中靶向G蛋白偶联受体的蛋白酶靶向嵌合体
Mol Pharmacol. 2025 Feb;107(2):100013. doi: 10.1016/j.molpha.2024.100013. Epub 2024 Dec 12.
9
An update on regulation and function of G protein-coupled receptors in cancer: A promising strategy for cancer therapy.G蛋白偶联受体在癌症中的调控与功能更新：一种有前景的癌症治疗策略。
Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189266. doi: 10.1016/j.bbcan.2025.189266. Epub 2025 Jan 27.
10
Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy.小分子 G 蛋白偶联受体家族靶向调节剂在肿瘤免疫治疗中的最新进展。
Curr Top Med Chem. 2019;19(16):1464-1483. doi: 10.2174/1568026619666190628115644.

本文引用的文献

1
The landscape of cancer-rewired GPCR signaling axes.癌症重编 GPCR 信号轴的景观。
Cell Genom. 2024 May 8;4(5):100557. doi: 10.1016/j.xgen.2024.100557.
2
Author Correction: IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.作者更正：白细胞介素-8是肝内胆管癌中一种新型促转移趋化因子，在CD97激活后可诱导CXCR2 - PI3K/AKT信号传导。
Sci Rep. 2024 Apr 11;14(1):8478. doi: 10.1038/s41598-024-58952-5.
3
Mast cells help organize the Peyer's patch niche for induction of IgA responses.
肥大细胞帮助组织派尔集合淋巴结腔室以诱导 IgA 应答。
Sci Immunol. 2024 Mar;9(93):eadj7363. doi: 10.1126/sciimmunol.adj7363. Epub 2024 Mar 1.
4
How chemokines organize the tumour microenvironment.趋化因子如何组织肿瘤微环境。
Nat Rev Cancer. 2024 Jan;24(1):28-50. doi: 10.1038/s41568-023-00635-w. Epub 2023 Dec 8.
5
Fasting-mimicking diet alleviates inflammatory pain by inhibiting neutrophil extracellular traps formation and neuroinflammation in the spinal cord.断食模拟饮食通过抑制中性粒细胞胞外诱捕网形成和脊髓神经炎症来缓解炎性疼痛。
Cell Commun Signal. 2023 Sep 21;21(1):250. doi: 10.1186/s12964-023-01258-2.
6
The gut microbiota-induced kynurenic acid recruits GPR35-positive macrophages to promote experimental encephalitis.肠道微生物群诱导的犬尿氨酸酸招募 GPR35 阳性巨噬细胞促进实验性脑炎。
Cell Rep. 2023 Aug 29;42(8):113005. doi: 10.1016/j.celrep.2023.113005. Epub 2023 Aug 16.
7
Activation of the GPR35 on ILC2 drives immunosuppression to promote lung cancer progression.ILC2 上 GPR35 的激活驱动免疫抑制以促进肺癌进展。
Am J Cancer Res. 2023 Jun 15;13(6):2426-2438. eCollection 2023.
8
The GPCR-Gα-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.G 蛋白偶联受体-Gα-蛋白激酶 A 信号轴促进 T 细胞功能障碍和癌症免疫治疗失败。
Nat Immunol. 2023 Aug;24(8):1318-1330. doi: 10.1038/s41590-023-01529-7. Epub 2023 Jun 12.
9
Platelets and mast cells promote pathogenic eosinophil recruitment during invasive fungal infection via the 5-HIAA-GPR35 ligand-receptor system.血小板和肥大细胞通过 5-HIAA-GPR35 配体-受体系统促进侵袭性真菌感染期间致病性嗜酸性粒细胞的募集。
Immunity. 2023 Jul 11;56(7):1548-1560.e5. doi: 10.1016/j.immuni.2023.05.006. Epub 2023 Jun 5.
10
Mast Cells and Resistance to Immunotherapy in Cancer.肥大细胞与癌症的免疫治疗抵抗。
Arch Immunol Ther Exp (Warsz). 2023 Apr 11;71(1):11. doi: 10.1007/s00005-023-00676-x.